Trump signs order easing ibogaine restrictions to boost mental‑health research

President Donald Trump signed an executive order on April 17 to ease restrictions on the psychedelic drug ibogaine, aiming to fast‑track mental‑health research. ^[1]

The move matters because it could expand treatment options for veterans and civilians suffering from severe depression, post‑traumatic stress disorder and traumatic brain injuries, conditions that have long outpaced existing therapies. Accelerating research may also position the U.S. as a leader in a field where other nations already allow clinical trials. ^[1]

The order directs the Food and Drug Administration to streamline approval processes for ibogaine studies and authorizes the National Institutes of Health to allocate additional funding for clinical trials. It also directs the Department of Health and Human Services to remove bureaucratic barriers that have limited researchers’ ability to obtain the drug for experimental use. ^[2]

Ibogaine, a plant‑derived psychedelic used in some African traditional medicines, has shown promise in small overseas studies for reducing withdrawal symptoms and alleviating depressive moods. U.S. regulators have classified it as a Schedule I substance, effectively banning its medical use despite anecdotal reports of benefit. By loosening these restrictions, the administration hopes to generate robust data that could lead to FDA‑approved indications. ^[1]

Advocates for mental‑health reform said the order shows the U.S. has lagged behind countries such as Canada and the United Kingdom in permitting controlled psychedelic research. Critics said easing controls without clear safety guidelines could expose vulnerable patients to unknown risks. The White House said the policy balances scientific urgency with patient protection, emphasizing that any clinical trial must meet existing ethical standards. ^[3]

The executive action reflects a broader shift in federal drug policy, echoing recent bipartisan bills that seek to reclassify certain psychedelics for therapeutic research. If successful, ibogaine studies could pave the way for additional compounds to enter the research pipeline, potentially reshaping the landscape of mental‑health treatment in the coming decade. ^[2]

**What this means** – By removing regulatory hurdles, the Trump administration is betting that scientific evidence will justify broader medical use of ibogaine. The decision could accelerate drug‑development timelines, attract private‑sector investment, and influence international standards for psychedelic research, while also raising questions about safety oversight and the pace of policy change.